Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 6.5% – Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price traded down 6.5% during mid-day trading on Thursday . The stock traded as low as $9.52 and last traded at $10.16. 24,316,392 shares traded hands during mid-day trading, a decline of 4% from the average session volume of 25,259,420 shares. The stock had previously closed at $10.87.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Trading Down 6.3 %

The firm’s 50-day simple moving average is $7.45 and its 200-day simple moving average is $6.98. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $3.98 billion, a PE ratio of -6.65 and a beta of 0.86.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in RXRX. Allspring Global Investments Holdings LLC bought a new position in shares of Recursion Pharmaceuticals during the third quarter valued at about $25,000. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals in the fourth quarter worth about $26,000. Private Trust Co. NA bought a new position in Recursion Pharmaceuticals in the fourth quarter worth about $27,000. GAMMA Investing LLC raised its stake in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after buying an additional 4,948 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.